The continuing UK ban on cannabis-based painkillers is unreasonable and inhumane|Simon Jenkins

November 11, 2019 by erfa5t8

That the government will permit a few serious epilepsy and multiple sclerosis sufferers to get cannabidiol medicine to eliminate their signs is excellent news. That is all that can be stated. Once more a decision emerges from the caverns of Britain’s NHS that reveals the evils of a politicised, centralised, deadened health service.

Legalisation of cannabis in the UK would help secure its users from harm|James Nicholls

Learn more

As it is, any cannabis medication which contains active THC as a pain reliever– as does medical cannabis for countless individuals worldwide– will stay banned. Medical cannabis may be offered throughout the free world. It might be readily available in Donald Trump’s America– where the president” backs medical marijuana 100%”. British patients might be able to cross the Channel and (illegally) import it. In your home, it can be purchased on practically every street corner, to be taken in by a < a href=" "title="" class=" u-underline” > reported 1.4 million Britons in discomfort. However British political leaders love playing doctor. The health secretary, Matt Hancock, has a basic election to fight. Discomfort must wait. He remains in the grip of a cannabis taboo– and big pharma.

Every loving parent of an epileptic kid knows what alleviates their pain. The idea that just a doctor with a prescription medication, clinically checked by a state regulator, can measure that discomfort is obscene. How many heartbreaking anecdotes are needed for Whitehall to take notification? This is what takes place when doctors solution to political leaders who answer to pharmaceutical companies with vested interests in existing products.

When last year, the then house secretary (note, not the health secretary), Sajid Javid, released licences for cannabis-based medications for kids in 2 highly publicised cases, it appeared progress was being made. However it ended up being simply a headline-grabbing gesture. Ranks quickly closed.

Hence the welcome, if desperate, initiative recently of DrugScience, led by the neuropsychopharmacologist David Nutt, to establish a 20,000-strong trial of client experience with medicinal cannabis. It is focused on conditions revealed to be prone to the drug, not simply epilepsy and MS however chronic pain, stress and anxiety, Tourette’s and post-traumatic tension. As Nutt states, it is simply wrong that ill patients in Britain need to be “ left without treatment, in substantial financial obligation from the expense of personal prescriptions, or criminalised as they are forced to turn to the black market“.

But the ultimate curse is main control over regional experiment. The advancement in the US came when the federal government was told it could not interfere in a state’s right to choose. So in this matter of marijuana, why not set Scotland free– free to welcome Britain to the 21st century?

- Simon Jenkins is a Guardian writer



Opinion< a class=" submeta

__ link” href=”” > Drugs( Society).


< a class=" submeta

__ link” href=”” >


Marijuana Products / Marijuana Today


Comments are closed.